These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33988834)

  • 21. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis.
    Wong YJ; Nguyen VH; Yang HI; Li J; Le MH; Wu WJ; Han NX; Fong KY; Chen E; Wong C; Rui F; Xu X; Xue Q; Hu XY; Leow WQ; Goh GB; Cheung R; Wong G; Wong VW; Yu MW; Nguyen MH
    Clin Mol Hepatol; 2023 Jul; 29(3):705-720. PubMed ID: 37157776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
    Lee HW; Lee JI; Kim S; Kim S; Chang HY; Lee KS
    BMC Gastroenterol; 2020 Apr; 20(1):113. PubMed ID: 32305059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.
    Kim GA; Lee HC; Kim MJ; Ha Y; Park EJ; An J; Lee D; Shim JH; Kim KM; Lim YS
    J Hepatol; 2015 May; 62(5):1092-9. PubMed ID: 25445399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.
    Song A; Wang X; Lu J; Jin Y; Ma L; Hu Z; Zheng Y; Shen C; Chen X
    J Viral Hepat; 2021 Apr; 28(4):601-612. PubMed ID: 33455067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance.
    Liu F; Wang XW; Chen L; Hu P; Ren H; Hu HD
    Aliment Pharmacol Ther; 2016 Jun; 43(12):1253-61. PubMed ID: 27117732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
    Gounder PP; Bulkow LR; Snowball M; Negus S; Spradling PR; Simons BC; McMahon BJ
    Aliment Pharmacol Ther; 2016 Jun; 43(11):1197-207. PubMed ID: 27061300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
    Chang FM; Wang YP; Lang HC; Tsai CF; Hou MC; Lee FY; Lu CL
    Hepatology; 2017 Sep; 66(3):896-907. PubMed ID: 28318053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study.
    Huang YW; Lee CL; Yang SS; Fu SC; Chen YY; Wang TC; Hu JT; Chen DS
    Am J Gastroenterol; 2016 Jul; 111(7):976-85. PubMed ID: 27166128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.
    Chen YC; Sheen IS; Chu CM; Liaw YF
    Gastroenterology; 2002 Oct; 123(4):1084-9. PubMed ID: 12360470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance.
    Seto WK; Tanaka Y; Wong DK; Shinkai N; Cheung KS; Liu KS; Fung J; Lai CL; Yuen MF
    Liver Int; 2016 May; 36(5):642-50. PubMed ID: 26474013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients.
    Yeo YH; Tseng TC; Hosaka T; Cunningham C; Fung JYY; Ho HJ; Kwak MS; Trinh HN; Ungtrakul T; Yu ML; Kobayashi M; Le AK; Henry L; Li J; Zhang J; Sriprayoon T; Jeong D; Tanwandee T; Gane E; Cheung RC; Wu CY; Lok AS; Lee HS; Suzuki F; Yuen MF; Kao JH; Yang HI; Nguyen MH
    Clin Transl Gastroenterol; 2020 Sep; 11(9):e00196. PubMed ID: 33094953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Jang JW; Kim JS; Kim HS; Tak KY; Nam H; Sung PS; Bae SH; Choi JY; Yoon SK; Roberts LR
    Clin Mol Hepatol; 2021 Jan; 27(1):207-218. PubMed ID: 33317255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.
    Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Wang LY; You SL; Iloeje UH; Chen CJ;
    Gastroenterology; 2010 Aug; 139(2):474-82. PubMed ID: 20434450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.
    Simon TG; Duberg AS; Aleman S; Hagstrom H; Nguyen LH; Khalili H; Chung RT; Ludvigsson JF
    Ann Intern Med; 2019 Sep; 171(5):318-327. PubMed ID: 31426090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    Yeh ML; Huang CF; Huang CI; Holmes JA; Hsieh MH; Tsai YS; Liang PC; Tsai PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chung RT; Yu ML
    J Hepatol; 2020 Jul; 73(1):62-71. PubMed ID: 32061869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Yip TC; Chan HL; Wong VW; Tse YK; Lam KL; Wong GL
    J Hepatol; 2017 Nov; 67(5):902-908. PubMed ID: 28652084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study.
    Park YM; Lee SG
    World J Gastroenterol; 2016 Nov; 22(44):9836-9843. PubMed ID: 27956808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Knowledge of Occult Hepatitis B Infection and Clinical Implications.
    Yip TC; Wong GL
    Semin Liver Dis; 2019 May; 39(2):249-260. PubMed ID: 30912100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
    Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
    Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Kuang XJ; Jia RR; Huo RR; Yu JJ; Wang JJ; Xiang BD; Li LQ; Peng Z; Zhong JH
    J Viral Hepat; 2018 Sep; 25(9):1026-1037. PubMed ID: 29624821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.